Idanuz (Icatibant)

Icatibant is a selective competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are the primary mechanisms that cause the swelling seen in hereditary angioedema attacks.

The dose of Idanuz is determined by the prescribing healthcare professional based on the patient’s clinical condition and regulatory guidelines. The prescriber will decide the exact amount and frequency required for each acute attack.

Safety data for icatibant in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To request Idanuz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Idanuz (icatibant) is a bradykinin B2 receptor antagonist, whereas other options such as C1‑esterase inhibitor concentrates replace a deficient protein, and newer monoclonal antibodies target different pathways. Icatibant offers a subcutaneous, rapid‑acting option that directly blocks bradykinin‑mediated swelling.

Idanuz should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

Idanuz is supplied as a solution for injection and is administered subcutaneously, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or, after proper instruction, by the patient or caregiver.

The most serious risks include severe allergic reactions such as anaphylaxis, angioedema involving the face or throat that could compromise the airway, and rare cases of hypotension. Patients should be monitored closely after administration for any signs of these reactions.

Idanuz is contraindicated in individuals with known hypersensitivity to icatibant or any of the formulation components. Caution is also advised for patients with a history of severe allergic reactions, uncontrolled hypertension, or those receiving ACE inhibitors without appropriate medical supervision.